30 years of research and long-term clinical experiences; 647 patients and 2,785 episodes treated in registrational studies and ~400 successful surgeries and procedures.1-23,a-c
What NovoSeven® RT means to your patients.
The experience continues
Portability to fit into your patients’ lives
Room temperature stable for fast access to treatment. Everything patients need to reconstitute is in one small box.1,d
Able to quickly treat bleeds when they occur
Rapid administration and infusion, leading to rapid activity.1,24
Proven effective for bleed resolution and surgery across 4 indications.1
A well-established safety profile
A low rate of thrombotic events based on clinical trials and registries.1,e
- 0.2% of bleeding episodes in patients with CHwI
- 4% of patients with AH
- <0.2% in patients with GT
And NovoSeven® RT is not made from human serum or human proteins.1,25
Miguel has CHBwI.
a1988: compassionate use initiated in the United States; 1999: FDA approval received for CHwI.25
bIncludes bleeding episodes, major and minor surgical procedures, traumatic injuries, and prophylaxis regimens.
cSuccess was defined differently in each study.
dPrior to reconstitution, store NovoSeven® RT powder and histidine diluent between 36-77˚F. After reconstitution, store NovoSeven® RT either at room temperature or refrigerated for up to 3 hours. Do not freeze reconstituted NovoSeven® RT or store in syringes.
eIn clinical trials and registries used to support licensure and in postmarketing surveillance, the overall rate of thrombosis was 0.17% of 12,288 bleeding and surgical episodes.26